NA
LENZ

Nordwand Advisors’s LENZ Therapeutics LENZ Stock Holding History

Nordwand Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-143
Closed -$2.97K – 179
2023
Q4 		$2.62K Hold
143
– – ﹤0.01% 141
2023
Q3 		$2.48K Hold
143
– – ﹤0.01% 115
2023
Q2 		$2.6K Hold
143
– – ﹤0.01% 109
2023
Q1 		$2.45K Buy
+143
New +$2.31K ﹤0.01% 116

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nordwand Advisors's LENZ Position: Q1 2024 in Review

Nordwand Advisors sold out of LENZ Therapeutics (LENZ) in Q1 2024, closing a stake of 143 shares — an estimated $2.97K sold.

Nordwand Advisors first reported a position in LENZ in Q1 2023 and held it in 4 quarters. The position peaked at $2.62K in Q4 2023. 55 funds tracked by Wall St. Rank hold LENZ as of Q1 2024.

  • Nordwand Advisors reported no remaining LENZ Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Nordwand Advisors sold 143 LENZ Therapeutics shares in Q1 2024, an estimated $2.97K.
  • Nordwand Advisors first reported a position in LENZ Therapeutics in Q1 2023 and held it in 4 quarters.
  • Nordwand Advisors's LENZ Therapeutics position peaked at $2.62K in Q4 2023.
  • 55 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2024.

Based on Nordwand Advisors's 13F filing for Q1 2024, filed 6 May 2024.